We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+7.34%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$314M
AUM Growth
-$11.8M
Cap. Flow
+$118M
Cap. Flow %
37.6%
Top 10 Hldgs %
75.78%
Holding
42
New
10
Increased
6
Reduced
8
Closed
11
Avg Time Held Equity + Options
2 quarters
Top 10 Avg Time Held Equity + Options
2.1 quarters
Top 20 Avg Time Held Equity + Options
1.7 quarters
Avg Time Held Equity only
2 quarters
Top 10 Avg Time Held Equity only
2.5 quarters
Top 20 Avg Time Held Equity only
2.2 quarters

Top Buys

Rank Stock Value
1
FAST icon
Fastenal
FAST
+$111M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$19.8M
3
ASND icon
Ascendis Pharma A/S
ASND
+$15.1M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$10.6M
5
EDIT icon
Editas Medicine
EDIT
+$9.51M

Top Sells

Rank Stock Value
1
DERM icon
Dermira, Inc.
DERM
+$15.4M
2
KA icon
Kineta, Inc. Common Stock
KA
+$9.39M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$9.27M
4
CYTK icon
Cytokinetics
CYTK
+$8.4M
5
AKAO
Achaogen Inc
AKAO
+$8.05M

Sector Composition

Rank Sector Weight
1 Healthcare 88.06%
2 Miscellaneous 9.92%
3 Industrials 2.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CYTK icon
26
Cytokinetics
CYTK
$8.57B
$667K 0.21%
54,879
-791,775
-94% -$8.4M
2015 Q4
4 quarters
TMBR
27
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$502K 0.16%
+89
New +$455K
2016 Q4
0 quarters
BMY icon
28
Bristol-Myers Squibb
BMY
$116B
$500K 0.16%
+8,560
New +$468K
2016 Q4
0 quarters
CASC
29
CALL
DELISTED
Cascadian Therapeutics, Inc.
CASC
$447K 0.14%
103,800
+86,500
+500% +$559K
2016 Q3
1 quarter
BMY icon
30
CALL
Bristol-Myers Squibb
BMY
$116B
– –
-500,000
Closed -$27M –
EXAS icon
31
PUT
DELISTED
Exact Sciences
EXAS
– –
-500,000
Closed -$9.29M –
FATE icon
32
Fate Therapeutics
FATE
$240M
– –
-590,527
Closed -$1.84M –
GILD icon
33
CALL
Gilead Sciences
GILD
$183B
– –
-150,000
Closed -$11.9M –
IRWD icon
34
CALL
Ironwood Pharmaceuticals
IRWD
$593M
– –
-336,111
Closed -$4.47M –
NTLA icon
35
Intellia Therapeutics
NTLA
$1.67B
– –
-200,858
Closed -$3.42M –
ONC icon
36
BeOne Medicines Ltd
ONC
$39.5B
– –
-163,470
Closed -$5.04M –
KA icon
37
DELISTED
Kineta, Inc. Common Stock
KA
– –
-4,302
Closed -$9.39M –
ONCE
38
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-68,600
Closed -$4.12M –
AKAO
39
DELISTED
Achaogen Inc
AKAO
– –
-1,679,707
Closed -$8.05M –
OMED
40
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
– –
-265,784
Closed -$3.04M –
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2016 Portfolio in Review

As of Q4 2016, EcoR1 Capital held 42 positions worth $314M, down 3.6% from $326M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

EcoR1 Capital deployed $118M of net new capital in Q4 2016, opening 10 new positions and adding to 6 existing holdings. Its largest new stake was Fastenal: 10,148,104 shares worth $6.37M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 80% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Dermira, Inc., an estimated $15.4M trimmed.

  • EcoR1 Capital's largest Q4 2016 buy was Fastenal: 10,148,104 shares worth $6.37M.
  • EcoR1 Capital added most to Ascendis Pharma A/S in Q4 2016, an estimated $15.1M increase.
  • EcoR1 Capital's biggest Q4 2016 reduction was Dermira, Inc., cutting an estimated $15.4M.
  • EcoR1 Capital fully exited Kineta, Inc. Common Stock in Q4 2016, selling an estimated $9.39M.
  • EcoR1 Capital's ten largest holdings make up 76% of its $314M portfolio in Q4 2016.
  • EcoR1 Capital opened 10 new positions and closed 11 in Q4 2016.
  • EcoR1 Capital's portfolio value fell 3.6% quarter-over-quarter to $314M.

Based on EcoR1 Capital's 13F filing for Q4 2016, filed 14 Feb 2017.